{"indexed":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T21:47:09Z","timestamp":1569448029723},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T00:00:00Z","timestamp":1300320000000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11102-011-0303-6","type":"article-journal","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T06:04:30Z","timestamp":1300255470000},"page":"25-29","source":"Crossref","is-referenced-by-count":29,"title":"Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience","prefix":"10.1007","volume":"15","author":[{"given":"Panagiotis","family":"Anagnostis","sequence":"first","affiliation":[]},{"given":"Fotini","family":"Adamidou","sequence":"additional","affiliation":[]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[]},{"given":"Zoe","family":"Efstathiadou","sequence":"additional","affiliation":[]},{"given":"Eleni","family":"Karathanassi","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Kita","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,3,17]]},"reference":[{"key":"303_CR1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265\u2013273","journal-title":"Clin Endocrinol (Oxf)"},{"key":"303_CR2","first-page":"104","volume":"68","author":"M Kars","year":"2010","unstructured":"Kars M, Dekkers OM, Pereira AM, Romijn JA (2010) Update in prolactinomas. Neth J Med 68:104\u2013112","journal-title":"Neth J Med"},{"key":"303_CR3","first-page":"65","volume":"45","author":"S Acquati","year":"2001","unstructured":"Acquati S, Pizzocaro A, Tomei G, Giovanelli M, Lib\u00e8 R, Faglia G, Ambrosi B (2001) A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurosurg Sci 45:65\u201369","journal-title":"J Neurosurg Sci"},{"key":"303_CR4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1012905415868","volume":"54","author":"P Nomikos","year":"2001","unstructured":"Nomikos P, Buchfelder M, Fahbusch R (2001) Current management of prolactinomas. J Neurooncol 54:139\u2013150","journal-title":"J Neurooncol"},{"key":"303_CR5","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jc.84.7.2518","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518\u20132522","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR6","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428\u20132436","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","volume":"22","author":"S Cannav\u00f2","year":"1999","unstructured":"Cannav\u00f2 S, Curt\u00f2 L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22:354\u2013359","journal-title":"J Endocrinol Invest"},{"key":"303_CR8","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jc.82.11.3574","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574\u20133579","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","volume":"2","author":"DG Johnston","year":"1984","unstructured":"Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet 2:187\u2013192","journal-title":"Lancet"},{"key":"303_CR10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0015-0282(16)47593-X","volume":"41","author":"WS Maxson","year":"1984","unstructured":"Maxson WS, Dudzinski M, Handwerger SH, Hammond CB (1984) Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil Steril 41:218\u2013223","journal-title":"Fertil Steril"},{"key":"303_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","volume":"34","author":"JW \u2018t Verlaat van","year":"1991","unstructured":"van \u2018t Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175\u2013178","journal-title":"Clin Endocrinol (Oxf)"},{"key":"303_CR12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","volume":"20","author":"M Muratori","year":"1997","unstructured":"Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537\u2013546","journal-title":"J Endocrinol Invest"},{"key":"303_CR13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/acta.0.1260489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D\u2019Alberton A, Crosignani P (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126:489\u2013494","journal-title":"Acta Endocrinol (Copenh)"},{"key":"303_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","volume":"63","author":"M Biswas","year":"2005","unstructured":"Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26\u201331","journal-title":"Clin Endocrinol (Oxf)"},{"key":"303_CR15","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jc.87.8.3578","volume":"87","author":"VQ Passos","year":"2002","unstructured":"Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578\u20133582","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0015-0282(16)59462-X","volume":"48","author":"C Rasmussen","year":"1987","unstructured":"Rasmussen C, Bergh T, Wide L (1987) Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertil Steril 48:550\u2013554","journal-title":"Fertil Steril"},{"key":"303_CR17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2265.2009.03657.x","volume":"72","author":"MS Huda","year":"2010","unstructured":"Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 72:507\u2013511","journal-title":"Clin Endocrinol (Oxf)"},{"key":"303_CR18","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao A, Di Sarno A, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023\u20132033","journal-title":"N Engl J Med"},{"key":"303_CR19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","volume":"67","author":"A Colao","year":"2007","unstructured":"Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67:426\u2013433","journal-title":"Clin Endocrinol (Oxf)"},{"key":"303_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P, J\u00f8rgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43\u201351","journal-title":"J Clin Endocrinol Metab"},{"key":"303_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53:53\u201360","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":"Pituitary","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0303-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-011-0303-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0303-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T08:16:32Z","timestamp":1560068192000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,17]]},"references-count":21,"journal-issue":{"published-print":{"date-parts":[[2012,3]]},"issue":"1"},"alternative-id":["303"],"URL":"http:\/\/dx.doi.org\/10.1007\/s11102-011-0303-6","relation":{"cites":[]},"ISSN":["1386-341X","1573-7403"],"subject":["Endocrinology, Diabetes and Metabolism","Endocrinology"],"container-title-short":"Pituitary"}